Figure S5 from CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Authors:
- Daniela CriscuoloDCDaniela Criscuolo
- Francesco MerollaFMFrancesco Merolla
- Benedetta PellegrinoBPBenedetta Pellegrino
- Luca RussolilloLRLuca Russolillo
- Ilaria De BenedictisIBIlaria De Benedictis
- Daniela CalifanoDCDaniela Califano
- Rosaria CatalanoRCRosaria Catalano
- Carmela BavielloCBCarmela Baviello
- Silvia VarricchioSVSilvia Varricchio
- Sabrina C. CecereSCSabrina C. Cecere
- Camilla NeroCNCamilla Nero
- Eleonora PalluzziEPEleonora Palluzzi
Open Access
- 26 January 2026
- other
- Published by American Association for Cancer Research (AACR)